Share on StockTwits
 

BioTelemetry (NASDAQ:BEAT) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a note issued to investors on Monday, AnalystRatings.Net reports. The firm currently has a $9.20 target price on the stock. Zacks‘ price objective points to a potential upside of 5.99% from the company’s current price.

A number of other firms have also recently commented on BEAT. Analysts at Benchmark Co. reiterated a “buy” rating on shares of BioTelemetry in a research note on Monday, February 3rd. They now have a $15.00 price target on the stock. Finally, analysts at Dougherty & Co reiterated a “buy” rating on shares of BioTelemetry in a research note on Wednesday, December 4th.

BioTelemetry (NASDAQ:BEAT) traded up 2.97% on Monday, hitting $8.68. The stock had a trading volume of 247,857 shares. BioTelemetry has a 52 week low of $2.30 and a 52 week high of $11.88. The stock has a 50-day moving average of $8.08 and a 200-day moving average of $8.83. The company’s market cap is $223.6 million.

BioTelemetry, Inc (NASDAQ:BEAT), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services.

To view Zacks’ full report, visit www.zacks.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.